Answers are grounded in this paper and cite their sources.
CLS-TA administered suprachoroidally in conjunction with intravitreal aflibercept for treatment of DME provides simliar visual benefit at 24 weeks' follow-up compared with aflibercept monotherapy, is well tolerated and shows modest anatomic benefit with potential to reduce treatment burden.
No takes yet. Share an insight, caveat, or question.
Barakat et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: